Knight Therapeutics (TSE:GUD) Hits New 1-Year High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high during trading on Wednesday. The stock traded as high as C$10.76 and last traded at C$10.73, with a volume of 30407 shares traded. The stock had previously closed at C$10.54.

Knight Therapeutics Trading Up 1.6%

The company has a debt-to-equity ratio of 4.29, a current ratio of 2.28 and a quick ratio of 1.79. The company has a market capitalization of C$1.05 billion, a price-to-earnings ratio of 71.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.45. The business has a fifty day moving average price of C$9.87 and a 200 day moving average price of C$8.99.

Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, August 6th. The company reported C($0.03) earnings per share (EPS) for the quarter. The company had revenue of C$143.97 million for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%. On average, equities analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.